Your browser doesn't support javascript.
loading
Biosafety standards for working with Crimean-Congo hemorrhagic fever virus.
Weidmann, Manfred; Avsic-Zupanc, Tatjana; Bino, Silvia; Bouloy, Michelle; Burt, Felicity; Chinikar, Sadegh; Christova, Iva; Dedushaj, Isuf; El-Sanousi, Ahmed; Elaldi, Nazif; Hewson, Roger; Hufert, Frank T; Humolli, Isme; Jansen van Vuren, Petrus; Koçak Tufan, Zeliha; Korukluoglu, Gülay; Lyssen, Pieter; Mirazimi, Ali; Neyts, Johan; Niedrig, Matthias; Ozkul, Aykut; Papa, Anna; Paweska, Janusz; Sall, Amadou A; Schmaljohn, Connie S; Swanepoel, Robert; Uyar, Yavuz; Weber, Friedemann; Zeller, Herve.
Affiliation
  • Weidmann M; Institute of Aquaculture, University of Stirling, Stirling, Scotland, UK.
  • Avsic-Zupanc T; Institute of Microbiology and Immunology, Medical Faculty of Ljubljana, Ljubljana, Slovenia.
  • Bino S; Institute of Public Health, Control of Infectious Diseases Department, Tirana, Albania.
  • Bouloy M; Institut Pasteur, Bunyaviruses Molecular Genetics, Paris, France.
  • Burt F; Department of Medical Microbiology and Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
  • Chinikar S; Laboratory of Arboviruses and Viral Hemorrhagic Fevers (National Ref Lab), Pasteur Institute of Iran, Tehran, Iran.
  • Christova I; National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
  • Dedushaj I; National Institute of Public Health in Kosovo, Pristina, Kosovo.
  • El-Sanousi A; Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
  • Elaldi N; Department of Infectious Diseases and Clinical Microbiology, Cumhuriyet University, Faculty of Medicine, Sivas, Turkey.
  • Hewson R; Public Health England, Porton Down, Wiltshire, Salisbury, UK.
  • Hufert FT; Institute of Microbiology and Virology, Brandenburg Medical School, Senftenberg, Germany.
  • Humolli I; National Institute of Public Health in Kosovo, Pristina, Kosovo.
  • Jansen van Vuren P; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Koçak Tufan Z; Infectious Diseases and Clinical Microbiology Department, Yildirim Beyazit University, Ankara Ataturk Training and Research Hospital, Ankara, Turkey.
  • Korukluoglu G; Public Health Institution of Turkey, Virology Reference and Research Laboratory, Ankara, Turkey.
  • Lyssen P; Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Mirazimi A; Institute for Laboratory Medicine, Department for Clinical Microbiology, Karolinska Institute, and Karolinska Hospital University, Stockholm, Sweden.
  • Neyts J; Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Niedrig M; Centre for Biological Threats and Special Pathogens, Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.
  • Ozkul A; Department of Virology, Ankara University, Faculty of Veterinary Medicine, Ankara, Turkey.
  • Papa A; Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Paweska J; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Sall AA; Arbovirus unit, Pasteur Institute, Dakar, Senegal.
  • Schmaljohn CS; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
  • Swanepoel R; Department of Veterinary Tropical Diseases, University of Pretoria, Pretoria, South Africa.
  • Uyar Y; Department of Medical Microbiology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Weber F; Institute for Virology, Justus Liebig-University Giessen, Giessen, Germany.
  • Zeller H; European Centre for Disease Prevention and Control, Stockholm, Sweden.
J Gen Virol ; 97(11): 2799-2808, 2016 Nov.
Article in En | MEDLINE | ID: mdl-27667586
ABSTRACT
In countries from which Crimean-Congo haemorrhagic fever (CCHF) is absent, the causative virus, CCHF virus (CCHFV), is classified as a hazard group 4 agent and handled in containment level (CL)-4. In contrast, most endemic countries out of necessity have had to perform diagnostic tests under biosafety level (BSL)-2 or -3 conditions. In particular, Turkey and several of the Balkan countries have safely processed more than 100 000 samples over many years in BSL-2 laboratories. It is therefore advocated that biosafety requirements for CCHF diagnostic procedures should be revised, to allow the tests required to be performed under enhanced BSL-2 conditions with appropriate biosafety laboratory equipment and personal protective equipment used according to standardized protocols in the countries affected. Downgrading of CCHFV research work from CL-4, BSL-4 to CL-3, BSL-3 should also be considered.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Occupational Exposure / Hemorrhagic Fever Virus, Crimean-Congo / Containment of Biohazards / Hemorrhagic Fever, Crimean Type of study: Guideline Limits: Animals / Humans Language: En Year: 2016 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Occupational Exposure / Hemorrhagic Fever Virus, Crimean-Congo / Containment of Biohazards / Hemorrhagic Fever, Crimean Type of study: Guideline Limits: Animals / Humans Language: En Year: 2016 Type: Article